Skip to main content
. Author manuscript; available in PMC: 2015 Jun 8.
Published in final edited form as: Cell. 1998 Apr 17;93(2):215–228. doi: 10.1016/s0092-8674(00)81573-1

Figure 8. Prevention of Calcineurin-Dependent Hypertrophy by CsA.

Figure 8

(A) The regimen for CsA treatment is shown.

(B) α-MHC-calcineurin transgenic (TG) and nontransgenic mice were treated with or without CsA (25 mg/kg body weight), as indicated. Heart-to-body weight ratios are expressed ± standard deviations. Transgenic littermates obtained from male calcineurin transgenic #37 (see Table 1) were injected subcutaneously twice daily with CsA or vehicle alone beginning at 9 days of age. At 25 days of age, animals were sacrificed and hearts were removed and sectioned longitudinally.

(C) H and E sections of hearts from nontransgenic (control) and transgenic mice treated with vehicle (center panel) or CsA (right panel). La, left atrium; lv, left ventricle; ra, right atrium; rv, right ventricle. The right atrium was removed from the control, and both atria were removed from the transgenic treated with CsA. Bar = 2 μm.